Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain

By Antonanzas Fernando   Rive Benoit   Badenas Josep   Gomez-Lus Susana   Guilhaume Chantal  

The European Journal of Health Economics, Vol. 7, Iss. 2, 2006-06 ,pp. : 137-144

Springer Publishing Company

Access to resources Recommend Favorite

Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy

By Sakka Paraskevi   Tsolaki Magda   Hort Jakub   Hager Klaus   Soininen Hilkka   López Pousa Secundino   Li Chunming   Schwam Elias  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3153-3165

Informa Healthcare

Access to resources Recommend Favorite

Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study

By Klinger Tatjana   Ibach Bernd   Schoenknecht Peter   Kamleiter Martin   Silver Gabrielle   Schroeder Johannes   Mielke Ruediger  

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 723-732

Informa Healthcare

Access to resources Recommend Favorite

EFNS‐ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 22, Iss. 6, 2015-06 ,pp. : 889-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

By Bullock Roger   Touchon Jacques   Bergman Howard   Gambina Giuseppe   He Yunsheng   Rapatz Günter   Nagel Jennifer   Lane Roger  

Current Medical Research and Opinion, Vol. 21, Iss. 8, 2005-08 ,pp. : 1317-1328

Informa Healthcare

Access to resources Recommend Favorite